# Quest Diagnostics (DGX) Stock Analysis: Insights into a 9.41% Upside Potential

- Link: https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-insights-into-a-9-41-upside-potential/4121244751
- Published: 2026-03-16T11:14:07+00:00
- Author: Madison Wilson

Quest Diagnostics Incorporated (NYSE: DGX), a prominent player in the healthcare
sector, specifically within the Diagnostics & Research industry, offers intriguing
prospects for individual investors. With a market capitalization of $22.22 billion,
this Secaucus, New Jersey-based company is a critical provider of diagnostic testing
and services across the United States. As we delve into its financial and strategic
positioning, Quest Diagnostics presents a compelling case for potential investors,
driven by its robust revenue growth and promising analyst ratings.

Currently trading at $199.70, Quest Diagnostics’ stock has seen a modest decline
of 0.01%, reflecting a price change of -1.18. However, with a 52-week range spanning
from $159.80 to $211.91, the stock demonstrates both resilience and room for growth.
Notably, the company’s forward price-to-earnings (P/E) ratio stands at 17.39, indicating
potential value for long-term investors.

Quest Diagnostics has shown impressive revenue growth of 7.10%, underscoring its
ability to expand its market presence and deliver consistent financial performance.
The company’s earnings per share (EPS) of 8.75 and a return on equity (ROE) of 14.75%
highlight its efficiency in generating shareholder returns. Additionally, the firm’s
free cash flow, reaching $1.011 billion, provides a solid foundation for sustainable
growth and potential future investments.

Investors seeking income will appreciate Quest Diagnostics’ dividend yield of 1.72%,
supported by a conservative payout ratio of 36.00%. This balance allows the company
to return capital to shareholders while retaining sufficient earnings for reinvestment
in its expansive diagnostic services portfolio.

Analyst sentiment towards Quest Diagnostics is predominantly positive, with nine
buy ratings, seven hold ratings, and just one sell rating. The target price range
between $184.00 and $235.00, with an average target of $218.50, indicates a potential
upside of 9.41%. Such projections suggest investor confidence in the company’s ability
to capitalize on its strategic initiatives and market opportunities.

From a technical perspective, Quest Diagnostics’ 50-day moving average of $193.89
and 200-day moving average of $183.02 indicate a stable upward trend. However, the
Relative Strength Index (RSI) of 31.30 suggests the stock may be approaching oversold
territory, possibly signaling a buying opportunity for astute investors.

Quest Diagnostics’ comprehensive suite of services, ranging from routine diagnostic
testing to advanced clinical assessments, positions it well to address the evolving
needs of healthcare providers, insurers, and patients. The company’s extensive network
of laboratories, patient service centers, and mobile health professionals enhances
its accessibility and service delivery capabilities.

In addition to its core diagnostic services, Quest Diagnostics is diversifying its
offerings with risk assessment services for the life insurance industry and healthcare
IT solutions. This strategic diversification aims to capture emerging opportunities
in the broader healthcare landscape, thereby bolstering its growth trajectory.

With a legacy dating back to 1967, Quest Diagnostics has established itself as a
trusted partner in the healthcare ecosystem. For investors seeking exposure to the
healthcare sector’s diagnostic and research domain, Quest Diagnostics offers a blend
of growth potential, reliable income, and strategic adaptability. As the company
continues to innovate and expand its service offerings, it remains a noteworthy 
addition to a well-rounded investment portfolio.

Share on:
